Güntner Drives Group-Wide Innovation in 2024 Sustainability Report
12.6.2025 22:30:00 EEST | Business Wire | Press release
Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/
Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts.
Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants across its product portfolio and continued investment in energy- and water-saving technologies at its global manufacturing facilities.
“Over the past few years, the way we talk about sustainability has changed,” said Christian Weiser, CEO of Güntner. “At Güntner, we have always approached sustainability with clarity. For us, it has never been about doing more, it has been about doing what matters, and that means focusing on impact.”
Highlights from the 2024 report include:
- Launch of the Impact° Label: Güntner’s Impact° label helps customers easily identify sustainable solutions, ranging from energy-efficient systems to products designed with natural refrigerants.
- First-Ever Impact Summit: In September 2024, Güntner hosted its inaugural Impact Summit in Budapest, bringing together nearly 190 customers from 36 countries. The three-day event showcased sustainable innovations and cross-industry collaboration, from AI-ready data center solutions to high-efficiency cold storage systems.
- Advancing Natural Refrigerants: Güntner is years ahead of schedule, with nearly all products already compatible with natural refrigerants like CO₂ and ammonia. A CO₂-compatible version of its GADV product family will launch in 2025, supporting the Group’s collective goal of achieving full portfolio readiness by 2030.
- Water Efficiency: Freshwater extraction has been reduced by nearly 20% since 2021, with a 30% efficiency improvement targeted by 2030. Güntner is helping drive this progress through continued investment in water-saving technologies across its global facilities.
- Pioneering Circular Economy Collaboration: In partnership with Circular Republic, Güntner is helping to launch the industry’s first product manufactured under circular economy principles. This effort includes design innovation, material reuse and multi-stakeholder partnerships focused on long-term sustainability.
These achievements are part of a broader Group-wide effort to reduce water and energy consumption, improve emissions performance and engage employees across all regions to build a more sustainable future.
To view the full report and learn more about Güntner’s sustainability initiatives, visit https://guntner.com/en-us/our-impact/sustainability-hub.
About Güntner
Güntner is a world-leading company in the manufacture of refrigeration and air conditioning equipment components. With more than 4,000 employees, offices in over 50 countries, and six manufacturing plants across Europe, Asia, and the Americas, the company shows a strong presence in all markets. Decades of experience in the industry and the consistent integration of the latest technologies and research findings ensure the high-quality standard of Güntner solutions. From fresh food and comfortable indoor temperatures in office buildings to data center solutions and energy production – Güntner plays an essential part in our daily lives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612897493/en/
Contacts
Media Contacts:
Lady Acuña - North America
Lady.acuna@guntner.com
Makenna Eldridge
makenna@reputationpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom